According to our results, one explanation for a successful reversion of PAH by BMP9 application would be that BMP9 would serve as an antagonist for TGFβ by competing with TGFβ for binding ALK1 and ALK2 in a mixed-heteromeric receptor complex. Here, ACVRL1 is linked to pulmonary arterial hypertension.